Once there's a COVID-19 vaccine, who'll get access?

Once there's a COVID-19 vaccine, who'll get access?

A Bangladeshi firm claims to have developed a COVID-19 vaccine that worked successfully in preliminary animal trial.

Still, he said that the country would likely have to pay more for any vaccine not developed with government funding.

Speaking at a parliamentary hearing on Wednesday afternoon, Gilbert reportedly said: "We're very happy that we're seeing the right sort of immune response that will give protection, and not the wrong sort".

Oxford University says that since people have already been infected by the adenovirus so now the human body knows how to make antibodies to fight the virus.

"We have not lost sight of our responsibility to the American people to maintain our regulatory independence and ensure our decisions related to all medical products, including COVID-19 vaccines, are based on science and the available data", said FDA commissioner Stephen Hahn.

"It is envisaged to launch the vaccine for public health use latest by 15th August 2020 after completion of all clinical trials".

The ChAdOx1 vaccine technology has been used to produce candidate vaccines against a number of pathogens including flu, chikungunya, Zika and another coronavirus, Middle East Respiratory Syndrome (MERS).

Scientists are reluctant to provide any "timeline" as to when the vaccine will be ready, as it is dependant on the results of clinical trials.

Ruth Faden, a bioethicist at Johns Hopkins University, is working to address these high-stakes issues as a member of the World Health Organization's COVID-19 Vaccines Working Group, a team of experts from different countries making recommendations on fair and equitable global access to a coronavirus vaccine.

The guidance also notes that, as more is learned about SARS-CoV-2 immunology and vaccine immune responses, consideration may be given to the FDA's Accelerated Approval pathway for vaccine licensure.

Related Articles